Mizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $110
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $96 to $110.
Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $96 to $110.